2-甲基丁酸氯甲酯 | 82504-44-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-甲基丁酸氯甲酯
• 英文名称: chloromethyl 2-methylbutanoate
• 英文别名: Chlormethyl-d,l-2-methylbutyrat
• CAS: 82504-44-7
• 化学式: C₆H₁₁ClO₂
• mdl: MFCD19232732
• 分子量: 150.605
• InChiKey: MGAJDLGBTVHGNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  149.4±13.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)
• 保留指数：
  934.8

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基丁酸氯甲酯 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 iodomethyl 2-methylbutanoate
  参考文献：
  名称：

  Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 2. Preparation and in vitro and in vivo evaluaton of 1-(alkoxymethyl)-2-[(hydroxyimino)methyl]-3-methylimidazolium halides for reactivation of organophosphorus-inhibited acetylcholinesterases

  摘要：

  A series of structurally related mono- and bis-1,3-disubstituted 2-[(hydroxyimino)methyl]imidazolium halides were evaluated in vitro for their ability to reactivate electric eel, bovine, and human erythrocyte (RBC) acetylcholinesterases (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP) and 3,3-dimethyl-2-butyl methyl-phosphonofluoridate (soman, GD). All new compounds were characterized for (hydroxyimino)methyl acid dissociation constant, nucleophilicity, octanol-buffer partition coefficient, reversible AChE inhibition, and kinetics of reactivation of EPMP-inhibited AChEs. For GD-inhibited AChEs, maximal reactivation was used to compare compounds since rapid phosphonyl enzyme dealkylation "aging" complicated interpretation of kinetic constants. For comparison, we also evaluated three known pyridinium therapeutics, 2-PAM, HI-6, and toxogonin. In vivo evaluation in mice revealed that when selected imidazolium compounds were coadministered with atropine sulfate, they were effective in providing lifesaving protection against both GD and EPMP challenges. This was a major accomplishment in the search for effective anticholinesterase therapeutics--the synthesis and preliminary evaluation of the first new monoquaternary soman antidotes with potencies superior to 2-PAM. Significantly, there was an apparent inverse relationship between in vitro and in vivo results; the most potent in vivo compounds proved to be the poorest in vitro reactivators. These results suggested that an alternative and possibly novel antidotal mechanism of protective action may be applicable for the imidazolium aldoximes. Selected compounds were also evaluated for their inhibition of AChE phosphorylation by GD and antimuscarinic and antinicotinic receptor blocking effects.

  DOI：

  10.1021/jm00122a034
• 作为产物：
  描述：

  聚合甲醛 、 2-甲基丁酰氯 在 zinc(II) chloride 作用下， 反应 0.75h， 生成 2-甲基丁酸氯甲酯
  参考文献：
  名称：

  软药品。3.一类新的抗胆碱能药。

  摘要：

  设计并合成了一类新的抗毒蕈碱药物。这些化合物是“软”季铵酯，其中只有一个碳原子将酯氧和季头分开。当衍生自受阻的“伞”酸时，该化合物是有效的抗胆碱能药，而当衍生自简单脂肪酸时，这些化合物是胆碱能药。与阿托品相比，更有效的抗胆碱能药具有高达10倍的乙酰胆碱拮抗剂活性，但作用时间却短得多。该化合物水解裂解，同时破坏四级头。该化合物有望作为选择性的局部药物，特别是作为内分泌出汗的抑制剂。

  DOI：

  10.1021/jm00179a002

文献信息

• [EN] SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS<br/>[FR] RÉACTIFS DE MÉTHYLFORMYLE SUBSTITUÉ ET PROCÉDÉ D'UTILISATION DE CEUX-CI POUR MODIFIER DES PROPRIÉTÉS PHYSICOCHIMIQUES ET/OU PHARMACOCINÉTIQUES DE COMPOSÉS
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2012137225A1

  公开（公告）日：2012-10-11

  The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/非手性取代甲基甲酰试剂，用于修改药物和/或生物活性物质，以改变未经修改的原始试剂产生的化合物的物理化学、生物学和/或药代动力学性质。
• NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES
  申请人：Inhibikase Therapeutics, Inc.

  公开号：US20140100225A1

  公开（公告）日：2014-04-10

  Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.

  小说化合物及其合成已被描述。还描述了在预防或治疗受试者中的癌症、细菌感染或病毒感染中使用这些化合物的方法。
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING KINASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR INHIBER LES KINASES
  申请人：INHIBIKASE THERAPEUTICS INC

  公开号：WO2018081251A1

  公开（公告）日：2018-05-03

  The present invention provides methods for the prevention or treatment of Parkinson's Disease using Abelson-family tyrosine kinase inhibitors.

  本发明提供了使用阿贝尔森家族酪氨酸激酶抑制剂预防或治疗帕金森病的方法。
• Soft drugs. 3. A new class of anticholinergic agents
  作者：Nicholas Bodor、Ross Woods、Colin Raper、Pauline Kearney、James J. Kaminski

  DOI：10.1021/jm00179a002

  日期：1980.5

  hindered "umbrella" acids and cholinergics when derivatives of simple aliphatic acids. The more potent anticholinergics have up to 10 times higher acetylcholine antagonist activity than atropine, but they have a much shorter duration of action. The compounds cleave hydrolytically with simultaneous destruction of the quaternary head. The compounds are promising as selective, local agents, particularly as

  设计并合成了一类新的抗毒蕈碱药物。这些化合物是“软”季铵酯，其中只有一个碳原子将酯氧和季头分开。当衍生自受阻的“伞”酸时，该化合物是有效的抗胆碱能药，而当衍生自简单脂肪酸时，这些化合物是胆碱能药。与阿托品相比，更有效的抗胆碱能药具有高达10倍的乙酰胆碱拮抗剂活性，但作用时间却短得多。该化合物水解裂解，同时破坏四级头。该化合物有望作为选择性的局部药物，特别是作为内分泌出汗的抑制剂。
• [EN] PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE PYRIDAZIN-3(2H)-ONE ET LEURS UTILISATION EN TANT QU'INHIBITEURS DE PDE4
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2005123693A1

  公开（公告）日：2005-12-29

  The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention and suppression of related pathological conditions, diseases and disorders, in particular asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, topic dermatitis, psoriasis or irritable bowel disease.

  该发明涉及新的治疗上有用的吡啶并嗪-3(2H)-酮衍生物，以及它们的制备方法和含有它们的药物组合物。这些化合物是磷酸二酯酶4（PDE4）的有效和选择性抑制剂，因此在治疗、预防和抑制相关病理条件、疾病和障碍方面具有用途，特别是哮喘、慢性阻塞性肺病、类风湿性关节炎、局部性皮炎、牛皮癣或肠易激综合征。